Blescath™ LaunchPosted On: May 3, 2022
BLEScath™ Launch May 5, 2022
We are excited to release a first-of-its-kind single-use, unique, intratracheal, thin catheter with an integrated stylet, designed by clinical experts who understand the practice and importance of delivering exogenous pulmonary surfactant to neonates who suffer from Neonatal Respiratory Distress Syndrome (NRDS)2.
BLEScath™ is intended for the administration of bovine lipid extract surfactant suspension (BLES®) using minimally invasive surfactant therapy (MIST) / less invasive surfactant administration (LISA) technique for rescue treatment of infants with NRDS2. BLEScath™ is intended for neonates at ≥ 28 weeks and or ≥ 1000 grams who do not require intubation or mechanical ventilation and meet the criteria for surfactant administration (i.e., oxygenation requirement met)1.
NRDS is a challenge mitigated by integrated scientific solutions. With the combination of BLEScath™ and use with BLES®, we are equipped to provide a broader range of product offerings and resources to address and lead innovation that compliments global surfactant delivery treatment to neonates experiencing NRDS. We have designed a user-friendly catheter for healthcare practitioners who are not familiar with intubation or the use of Magill forceps3.
1.BLES® Product Monograph, January 31, 2022.
2.BLEScath™ Instructions for Use (IFU) December 31, 2020.
3.Herting E, Härtel C, Göpel W. Less invasive surfactant administration. Current Opinion in Pediatrics.2020;32(2):228–34.